Stepwise Introduction of Elexacaftor-Tezacaftor-Ivacaftor in Patients With Cystic Fibrosis and Liver Cirrhosis Child-Pugh A or B Using Clinical and Therapeutic Drug Monitoring: A Case Series
Clin Ther. 2023 Dec 1:S0149-2918(23)00433-2. doi: 10.1016/j.clinthera.2023.11.003. Online ahead of print.ABSTRACTPURPOSE: Cystic fibrosis (CF) is a monogenetic disease caused by mutations in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR) protein and affecting multiple organs, including the lungs and liver. Almost 90% of people affected carry at least 1 Phe508del CFTR mutation. Medical treatment with the CFTR-modulating drug elexacaftor-tezacaftor-ivacaftor (ETI) has been proven to be efficacious in carriers of at least 1 Phe508del CFTR mutation. Use of ETI in patients with CF (pwCF) and li...
Source: Clinical Therapeutics - December 2, 2023 Category: Drugs & Pharmacology Authors: Steffie E M Vonk Rianne Lub Els J M Weersink Ulrich Beuers Ron A A Math ôt E Marleen Kemper Josje Altenburg Amsterdam Mucociliary Clearance Disease Research Group Source Type: research
Zuranolone
Clin Ther. 2023 Dec 1:S0149-2918(23)00443-5. doi: 10.1016/j.clinthera.2023.11.006. Online ahead of print.NO ABSTRACTPMID:38042632 | DOI:10.1016/j.clinthera.2023.11.006 (Source: Clinical Therapeutics)
Source: Clinical Therapeutics - December 2, 2023 Category: Drugs & Pharmacology Authors: Paul Beninger Source Type: research
Stepwise Introduction of Elexacaftor-Tezacaftor-Ivacaftor in Patients With Cystic Fibrosis and Liver Cirrhosis Child-Pugh A or B Using Clinical and Therapeutic Drug Monitoring: A Case Series
Clin Ther. 2023 Dec 1:S0149-2918(23)00433-2. doi: 10.1016/j.clinthera.2023.11.003. Online ahead of print.ABSTRACTPURPOSE: Cystic fibrosis (CF) is a monogenetic disease caused by mutations in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR) protein and affecting multiple organs, including the lungs and liver. Almost 90% of people affected carry at least 1 Phe508del CFTR mutation. Medical treatment with the CFTR-modulating drug elexacaftor-tezacaftor-ivacaftor (ETI) has been proven to be efficacious in carriers of at least 1 Phe508del CFTR mutation. Use of ETI in patients with CF (pwCF) and li...
Source: Clinical Therapeutics - December 2, 2023 Category: Drugs & Pharmacology Authors: Steffie E M Vonk Rianne Lub Els J M Weersink Ulrich Beuers Ron A A Math ôt E Marleen Kemper Josje Altenburg Amsterdam Mucociliary Clearance Disease Research Group Source Type: research
Zuranolone
Clin Ther. 2023 Dec 1:S0149-2918(23)00443-5. doi: 10.1016/j.clinthera.2023.11.006. Online ahead of print.NO ABSTRACTPMID:38042632 | DOI:10.1016/j.clinthera.2023.11.006 (Source: Clinical Therapeutics)
Source: Clinical Therapeutics - December 2, 2023 Category: Drugs & Pharmacology Authors: Paul Beninger Source Type: research
Stepwise Introduction of Elexacaftor-Tezacaftor-Ivacaftor in Patients With Cystic Fibrosis and Liver Cirrhosis Child-Pugh A or B Using Clinical and Therapeutic Drug Monitoring: A Case Series
Clin Ther. 2023 Dec 1:S0149-2918(23)00433-2. doi: 10.1016/j.clinthera.2023.11.003. Online ahead of print.ABSTRACTPURPOSE: Cystic fibrosis (CF) is a monogenetic disease caused by mutations in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR) protein and affecting multiple organs, including the lungs and liver. Almost 90% of people affected carry at least 1 Phe508del CFTR mutation. Medical treatment with the CFTR-modulating drug elexacaftor-tezacaftor-ivacaftor (ETI) has been proven to be efficacious in carriers of at least 1 Phe508del CFTR mutation. Use of ETI in patients with CF (pwCF) and li...
Source: Clinical Therapeutics - December 2, 2023 Category: Drugs & Pharmacology Authors: Steffie E M Vonk Rianne Lub Els J M Weersink Ulrich Beuers Ron A A Math ôt E Marleen Kemper Josje Altenburg Amsterdam Mucociliary Clearance Disease Research Group Source Type: research
Zuranolone
Clin Ther. 2023 Dec 1:S0149-2918(23)00443-5. doi: 10.1016/j.clinthera.2023.11.006. Online ahead of print.NO ABSTRACTPMID:38042632 | DOI:10.1016/j.clinthera.2023.11.006 (Source: Clinical Therapeutics)
Source: Clinical Therapeutics - December 2, 2023 Category: Drugs & Pharmacology Authors: Paul Beninger Source Type: research
Alcohol in 2023: Addressing Unmet Needs Through Pharmacotherapy and Integrated Care
Clin Ther. 2023 Nov 30:S0149-2918(23)00426-5. doi: 10.1016/j.clinthera.2023.10.017. Online ahead of print.NO ABSTRACTPMID:38040534 | DOI:10.1016/j.clinthera.2023.10.017 (Source: Clinical Therapeutics)
Source: Clinical Therapeutics - December 1, 2023 Category: Drugs & Pharmacology Authors: Alfred Sidney Barritt Source Type: research
Estimating Changes in Weight and Metabolic Parameters Before and After Treatment With Cariprazine: A Retrospective Study of Electronic Health Records
Clin Ther. 2023 Nov 29:S0149-2918(23)00407-1. doi: 10.1016/j.clinthera.2023.10.015. Online ahead of print.ABSTRACTPURPOSE: Weight gain and associated negative cardiometabolic effects can occur as a result of mental illness or treatment with second-generation antipsychotics (SGAs), leading to increased rates of morbidity and mortality. In this analysis, we evaluated the effect of the SGA cariprazine on weight and metabolic parameters in a real-world, retrospective, observational dataset.METHODS: Electronic health records from the Optum Humedica database (October 1, 2014-December 31, 2020) were analyzed during the 12-month p...
Source: Clinical Therapeutics - November 30, 2023 Category: Drugs & Pharmacology Authors: Prakash S Masand Roger S McIntyre Andrew J Cutler Michael L Ganz Andrea L Lorden Kiren Patel Ken Kramer Amanda Harrington Huy-Binh Nguyen Source Type: research
Estimating Changes in Weight and Metabolic Parameters Before and After Treatment With Cariprazine: A Retrospective Study of Electronic Health Records
Clin Ther. 2023 Nov 29:S0149-2918(23)00407-1. doi: 10.1016/j.clinthera.2023.10.015. Online ahead of print.ABSTRACTPURPOSE: Weight gain and associated negative cardiometabolic effects can occur as a result of mental illness or treatment with second-generation antipsychotics (SGAs), leading to increased rates of morbidity and mortality. In this analysis, we evaluated the effect of the SGA cariprazine on weight and metabolic parameters in a real-world, retrospective, observational dataset.METHODS: Electronic health records from the Optum Humedica database (October 1, 2014-December 31, 2020) were analyzed during the 12-month p...
Source: Clinical Therapeutics - November 30, 2023 Category: Drugs & Pharmacology Authors: Prakash S Masand Roger S McIntyre Andrew J Cutler Michael L Ganz Andrea L Lorden Kiren Patel Ken Kramer Amanda Harrington Huy-Binh Nguyen Source Type: research
The Effect of Berberine Supplementation on Glycemic Control and Inflammatory Biomarkers in Metabolic Disorders: An Umbrella Meta-Analysis of Randomized Controlled Trials
Clin Ther. 2023 Nov 27:S0149-2918(23)00429-0. doi: 10.1016/j.clinthera.2023.10.019. Online ahead of print.ABSTRACTPURPOSE: Several meta-analyses reported berberine (BBR) supplementation improves glycemic parameters and inflammatory marker, but findings remain inconsistent. Therefore, this study was conducted.METHODS: We systematically searched PubMed, Embase, Web of Science, Scopus, and Google Scholar to identify the relevant meta-analyses up to April 2023.FINDINGS: BBR supplementation was effective in reducing fasting blood glucose (FBG) (ESWMD: -0.77; 95% CI: -0.90 to -0.63, and ESSMD: -0.65; 95% CI: -0.83 to -0.47), hem...
Source: Clinical Therapeutics - November 28, 2023 Category: Drugs & Pharmacology Authors: Ahmad Nazari Zahra Rostami Ghotbabadi Kimia Sadat Kazemi Yalda Metghalchi Reza Tavakoli Razieh Ziaei Rahimabadi Mohammad Ghaheri Source Type: research
The Effect of Berberine Supplementation on Glycemic Control and Inflammatory Biomarkers in Metabolic Disorders: An Umbrella Meta-Analysis of Randomized Controlled Trials
Clin Ther. 2023 Nov 27:S0149-2918(23)00429-0. doi: 10.1016/j.clinthera.2023.10.019. Online ahead of print.ABSTRACTPURPOSE: Several meta-analyses reported berberine (BBR) supplementation improves glycemic parameters and inflammatory marker, but findings remain inconsistent. Therefore, this study was conducted.METHODS: We systematically searched PubMed, Embase, Web of Science, Scopus, and Google Scholar to identify the relevant meta-analyses up to April 2023.FINDINGS: BBR supplementation was effective in reducing fasting blood glucose (FBG) (ESWMD: -0.77; 95% CI: -0.90 to -0.63, and ESSMD: -0.65; 95% CI: -0.83 to -0.47), hem...
Source: Clinical Therapeutics - November 28, 2023 Category: Drugs & Pharmacology Authors: Ahmad Nazari Zahra Rostami Ghotbabadi Kimia Sadat Kazemi Yalda Metghalchi Reza Tavakoli Razieh Ziaei Rahimabadi Mohammad Ghaheri Source Type: research
The Effect of Berberine Supplementation on Glycemic Control and Inflammatory Biomarkers in Metabolic Disorders: An Umbrella Meta-Analysis of Randomized Controlled Trials
Clin Ther. 2023 Nov 27:S0149-2918(23)00429-0. doi: 10.1016/j.clinthera.2023.10.019. Online ahead of print.ABSTRACTPURPOSE: Several meta-analyses reported berberine (BBR) supplementation improves glycemic parameters and inflammatory marker, but findings remain inconsistent. Therefore, this study was conducted.METHODS: We systematically searched PubMed, Embase, Web of Science, Scopus, and Google Scholar to identify the relevant meta-analyses up to April 2023.FINDINGS: BBR supplementation was effective in reducing fasting blood glucose (FBG) (ESWMD: -0.77; 95% CI: -0.90 to -0.63, and ESSMD: -0.65; 95% CI: -0.83 to -0.47), hem...
Source: Clinical Therapeutics - November 28, 2023 Category: Drugs & Pharmacology Authors: Ahmad Nazari Zahra Rostami Ghotbabadi Kimia Sadat Kazemi Yalda Metghalchi Reza Tavakoli Razieh Ziaei Rahimabadi Mohammad Ghaheri Source Type: research
Health Care Resource Utilization and Total Costs of Care for Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia in the United States: A Retrospective Claims Analysis
This study assessed real-world HRU and costs of care among adult patients with R/R B-ALL by line of therapy (LoT) in the United States.METHODS: We selected patients from the MarketScanⓇ Database (January 1, 2016 through December 31, 2020) as follows: ≥1 claims of ALL-indicated first-line (1L) therapies, ≥1 diagnosis of ALL before the index date (1L initiation date), 6-month continuous enrollment before the index date, second-line (2L) therapy initiation, ≥18 years old at 2L, no clinical trial enrollment, no diagnosis of other forms of non-Hodgkin's lymphoma, and no claim for daratumumab or nelarabine during the stu...
Source: Clinical Therapeutics - November 19, 2023 Category: Drugs & Pharmacology Authors: Diane Ito Chaoling Feng Christine Fu Chong Kim James Wu David Dalton Josh Epstein Julia T Snider Adam S DuVall Source Type: research
Health Care Resource Utilization and Total Costs of Care for Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia in the United States: A Retrospective Claims Analysis
This study assessed real-world HRU and costs of care among adult patients with R/R B-ALL by line of therapy (LoT) in the United States.METHODS: We selected patients from the MarketScanⓇ Database (January 1, 2016 through December 31, 2020) as follows: ≥1 claims of ALL-indicated first-line (1L) therapies, ≥1 diagnosis of ALL before the index date (1L initiation date), 6-month continuous enrollment before the index date, second-line (2L) therapy initiation, ≥18 years old at 2L, no clinical trial enrollment, no diagnosis of other forms of non-Hodgkin's lymphoma, and no claim for daratumumab or nelarabine during the stu...
Source: Clinical Therapeutics - November 19, 2023 Category: Drugs & Pharmacology Authors: Diane Ito Chaoling Feng Christine Fu Chong Kim James Wu David Dalton Josh Epstein Julia T Snider Adam S DuVall Source Type: research
Health Care Resource Utilization and Total Costs of Care for Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia in the United States: A Retrospective Claims Analysis
This study assessed real-world HRU and costs of care among adult patients with R/R B-ALL by line of therapy (LoT) in the United States.METHODS: We selected patients from the MarketScanⓇ Database (January 1, 2016 through December 31, 2020) as follows: ≥1 claims of ALL-indicated first-line (1L) therapies, ≥1 diagnosis of ALL before the index date (1L initiation date), 6-month continuous enrollment before the index date, second-line (2L) therapy initiation, ≥18 years old at 2L, no clinical trial enrollment, no diagnosis of other forms of non-Hodgkin's lymphoma, and no claim for daratumumab or nelarabine during the stu...
Source: Clinical Therapeutics - November 19, 2023 Category: Drugs & Pharmacology Authors: Diane Ito Chaoling Feng Christine Fu Chong Kim James Wu David Dalton Josh Epstein Julia T Snider Adam S DuVall Source Type: research
